Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech vs. Shorts -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (316)	1/14/2000 10:14:00 AM
From: KewlHand	Respond to of 427

Peter, the total open interest on calls through to April is less than 3500 contracts, ie 350000 stock, and I own a decent chunk of them! ;) I would tend to agree my investment in a single stock (or options) is on the face of it highly risky. But the more I look into this company the more convinced I am that they are going to succeed and big time. Terms like $1000 stock are emotive as every stock is potentially $1000 stock, it's only a question of how long. Let me attach my own target instead $200 by this time next year. The cancer market (remember their drugs are proving to be generic, not just specific to one cancer type) is huge!!! JMHO regards kh TFDW

To: Biomaven who wrote (316)	1/14/2000 11:15:00 AM
From: Neuroguy	Read Replies (2) \| Respond to of 427

Peter - emotive valuations of CLPA aside, it still falls into a category of a pretty classic short squeeze. A lot of big money is lined up to buy upon FDA approval, and when the price hits $20, the market cap reaches the magic $500M number. Both events will make it a potential buying target for various funds. I can confirm KewlHand's estimate of late jan/early Feb for approval, but my crystal ball is a tad dusty as regards price predictions. A major fund manager quoted $50-70 by the summer, and $100-150 in a year. No idea where he derived those estimates from. $20-30 over the next month is certainly expected. Are you still in SEPR? It's doing very nicely of late.